Table 1 Demographic and treatment characteristics of study participants

Sex (male:female)

12:10

16:6

11:13

18:5

56:36

ns

Age in years

36 (22–61)

45 (20–73)

41 (21–65)

46 (27–62)

44 (20–73)

ns

Months since HIV-diagnosis

0 (0–101)

30 (3–207)

152 (32–305)

155 (50–302)

–

***

CD4 nadir (× 10⁶ cells/l)

170 (30–250)

480 (300–1000)

175 (0–310)

150 (0–470)

–

***

CD4 at baseline (× 10⁶ cells/l)

170 (40–250)

605 (520–1000)

565 (360–1100)

470 (270–900)

–

***

HIV RNA (log₁₀ copies/ml)

4.89 (2.89–5.93)

3.87 (< 1.28–5.12)

All < 1.28

All < 1.28

–

***

Pre-ART HIV RNA (log₁₀ copies/ml)

–

–

5.05 (2.63–6.62)

4.88 (2.92–5.79)

–

**

Treatment duration (months)

–

–

57 (28–204)

77 (28–210)

–

ns

Apolipoprotein B (g/L)

0.81 (0.47–1.40)

0.92 (0.47–1.40)

1.10 (0.33–1.50)

1.00 (0.47–1.80)

0.87 (0.42–2.20)

*

Apolipoprotein A1 (g/L)

1.40 (0.76–2.10)

1.45 (0.94–1.90)

1.55 (1.10–1.90)

1.70 (1.10–2.80)

1.50 (1.10–2.60)

ns

Total cholesterol (mmol/L)

4.2 (3.0–8.4)

5.0 (3.6–7.1)

5.7 (2.4–7.8)

6.0 (3.6–9.5)

–

***

HDL-cholesterol (mmol/L)

1.3 (0.6–2.1)

1.3 (0.6–2.1)

1.2 (0.9–2.0)

1.5 (0.9–2.7)

–

ns

Triglycerides (mmol/L)

1.20 (0.49–4.30)

1.45 (0.50–2.50)

2.15 (0.78–9.40)

1.70 (0.71–12.00)

–

**

hsCRP (mg/L)

2.75 (0.17–50.00)

1.60 (0.00–12.00)

1.40 (0.00–14.00)

3.50 (0.34–11.00)

0.63 (0.0–36.00)

***

Soluble CD14 (ng/mL)

1333 (991–3762)

1491 (842–1888)

1621 (1067–2283)

1796 (1228–3528)

1259 (872–2131)

***